UTILIZATION OF MODIFIED VACCINIA ANKARA VIRUS (MVA) WITH GENES THAT ENCODE FOR THE TOXOPLASMA GONDII SAG1 SURFACE PROTEIN, AS VACCINES AGAINST TOXOPLASMOSIS
The present invention concerns to recombinant influenza viruses and modified vaccinia Ankara viruses (MVA), and to a process for construction of recombinant influenza viruses and modified vaccinia Ankara viruses (MVA) with genes that encode for the T. gondii parasite SAG1 (MVA) and SAG2 (MVA and influenza) proteins, by means of a homologous recombination technique between two transfer vectors (for construction of MVA virus) and reverse genetics (for construction of influenza virus). Additionally, the present invention describes a vaccine composition using recombinant influenza viruses and modified vaccinia Ankara viruses (MVA), or recombinant adenoviruses and modified vaccinia Ankara viruses (MVA), for immunization against infections caused by the T. gondii parasite. Finally, the present invention describes a novel immunization method against infections or tumoral diseases, using recombinant influenza virus and adenovirus, in heterologous protocols of immune response induction and enhancement.
